Reported about 12 hours ago
Regeneron Pharmaceuticals will purchase bankrupt genetic testing company 23andMe for $256 million, aiming to enhance its genomics capabilities with over 15 million customer DNA profiles. The acquisition raises concerns over data privacy, especially after 23andMe's recent data breach revealed sensitive information of millions. Regeneron committed to upholding existing privacy policies and complying with data protection laws, while an independent overseer will monitor the deal's impact on consumer privacy. The transaction is set for approval on June 17.
Source: YAHOO